Previously, in two phase III trials, it was proven that a combination therapy with dabrafenib and trametinib improves PFS compared with dabrafenib alone (NCT01597908) or with vemurafenib alone (NCT01597908) in patients with BRAF mutant metastatic melanoma [124,125]. This evidence concerns the gene BRAF and metastatic melanoma.